Comparison of clindamycin and metronidazole in treating vaginitis

Ke Ding

doi:10.54254/2753-8818/45/20240595

Research Article

Open access

Published on 26 July 2024

Download pdf

Ding,K. (2024). Comparison of clindamycin and metronidazole in treating vaginitis. Theoretical and Natural Science,45,239-247.

Export citation

Comparison of clindamycin and metronidazole in treating vaginitis

Ke Ding *^,1,

¹ Nanjing University of Chinese Medicine

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/45/20240595

Abstract

Vaginitis is a common gynecological condition, often caused by a variety of pathogens and influenced by external factors as well as hormonal fluctuations. Among the various types of vaginitis, bacterial vaginosis stands out as a significant concern affecting countless women worldwide. This article aims to provide an in-depth understanding of vaginitis, its historical development, and its multifaceted causes. Furthermore, we will explore relationship between clindamycin and lincosamides, offering an informative introduction to the class of antibiotics known as lincosamides. In this paper, we will illustrate the specifics of two prominent drugs—clindamycin and metronidazole. This article contains their respective backgrounds, chemical structures, mechanisms of action and pharmaceutical synthesis. To provide a comprehensive overview, this paper will also incorporate findings from clinical trials, which play a crucial role in assessing the safety, cost containment strategies, and overall efficacy of clindamycin and metronidazole in the treatment of vaginitis.

Keywords

vaginitis, clindamycin, metronidazole, trial

View pdf

References

[1]. Bautista, C. T., Wurapa, E., Sateren, W. B., Morris, S., Hollingsworth, B., & Sanchez, J. L. (2016). Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Military Medical Research, 3, 4. https://doi.org/10.1186/s40779-016-0074-5

[2]. Morar, M., Bhullar, K., Hughes, D. W., Junop, M., & Wright, G. D. (2009). Structure and mechanism of the lincosamide antibiotic adenylyltransferase LinB. Structure (London, England: 1993), 17(12), 1649–1659. https://doi.org/10.1016/j.str.2009.10.013

[3]. Johnson, M. D., & Decker, C. F. (2008). Antimicrobial agents in treatment of MRSA infections. Disease-a-month : DM, 54(12), 793–800. https://doi.org/10.1016/j.disamonth.2008.09.002

[4]. Fitzhugh A. L. (1998). Antibiotic inhibitors of the peptidyl transferase center. 1. Clindamycin as a composite analogue of the transfer RNA fragments L-Pro-Met and the D-ribosyl ring of adenosine. Bioorganic & medicinal chemistry letters, 8(1), 87–92. https://doi.org/10.1016/s0960-894x(97)10196-2

[5]. DrugBank. (n.d.). Clindamycin - DrugBank. Retrieved from https://www.drugbank.ca/drugs/DB01190

[6]. Murphy, P. B., Bistas, K. G., & Le, J. K. (2023, May 23). Clindamycin. In StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK519574/

[7]. Medicines.org.uk. (n.d.). Clindamycin 150Mg Capsules-Summary Of Product Characteristics (Smpc) - (Emc). Retrieved from https://www.medicines.org.uk/emc/medicine/21628

[8]. De Cruz, R., Ferguson, J., Wee, J. S., & Akhras, V. (2015). Acute localised exanthematous pustulosis (ALEP) induced by clindamycin in pregnancy. The Australasian journal of dermatology, 56(3), e55–e58. https://doi.org/10.1111/ajd.12135

[9]. Drugs.com. (n.d.). Clindamycin Prices, Coupons & Patient Assistance Programs - Drugs.Com. Retrieved from https://www.drugs.com/price-guide/clindamycin

[10]. DrugBank. (n.d.). Metronidazole - DrugBank. Retrieved from https://go.drugbank.com/drugs/DB00916

[11]. Weir, C. B., & Le, J. K. (2023, February 12). Metronidazole. In StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK539728/

[12]. Ahmed, F. (2022, April). Mechanism of action figure 2 above illustrates how metronidazole undergo therapeutic response ResearchGate. https://www.researchgate.net/figure/Mechanism-of-Action-Figure-2-above-illustrates-how-metronidazole-undergo-therapeutic_fig1_351867679

[13]. Vardanyan, R. S., & Hruby, V. J. (2006). Synthesis of Essential Drugs. In Synthesis of Essential Drugs (pp. 559-582). Department of Chemistry 1306 E. University. Retrieved May 9, 2007, from https://doi.org/10.1016/B978-044452166-8/50037-6

[14]. Lamp, K. C., Freeman, C. D., Klutman, N. E., & Lacy, M. K. (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clinical pharmacokinetics, 36(5), 353–373. https://doi.org/10.2165/00003088-199936050-00004

[15]. Senthilkumaran, S., Shah, S., Balamurugan, N., & Thirumalaikolundusubramanian, P. (2015). Metronidazole encephalopathy: Uncommon reaction to a common drug. International journal of critical illness and injury science, 5(2), 123–124. https://doi.org/10.4103/2229-5151.158422

[16]. Hernández Ceruelos, A., Romero-Quezada, L. C., Ruvalcaba Ledezma, J. C., & López Contreras, L. (2019). Therapeutic uses of metronidazole and its side effects: an update. European review for medical and pharmacological sciences, 23(1), 397–401. https://doi.org/10.26355/eurrev_201901_16788

[17]. Andres, F. J., Parker, R., Hosein, I., & Benrubi, G. I. (1992). Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial. Southern medical journal, 85(11), 1077–1080. https://doi.org/10.1097/00007611-199211000-00006

[18]. Jung, B., & Andrews, J. D. (1990). Effectiveness of an antibiotic cost containment measure. The Canadian journal of hospital pharmacy, 43(3), 116–122.

[19]. Jung, B., & Andrews, J. D. (1990). Effectiveness of an antibiotic cost containment measure. The Canadian journal of hospital pharmacy, 43(3), 116-122.

Cite this article

Ding,K. (2024). Comparison of clindamycin and metronidazole in treating vaginitis. Theoretical and Natural Science,45,239-247.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health

Conference website: https://www.icmmgh.org/

ISBN：978-1-83558-551-1(Print) / 978-1-83558-552-8(Online)

Conference date: 5 January 2024

Editor：Mohammed JK Bashir

Series: Theoretical and Natural Science

Volume number: Vol.45

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).